## WHAT IS THE PURPOSE OF THE STUDY?

The purpose of this study is to learn more about the effects of an experimental combination treatment of **pozelimab** and **cemdisiran**, to see how well-tolerated and effective they are compared to an already approved treatment, ravulizumab. These study drugs are known as "complement inhibitors."

**Pozelimab** and **cemdisiran** may work together to reduce the levels and activity of C5, a protein involved in the destruction of red blood cells in people with PNH.



**Ravulizumab** is a drug that blocks the activity of C5 and is approved for the treatment of PNH in some countries.

## WHO IS THE STUDY FOR?

This study is for adults 18 years of age or older who:

- Have a confirmed diagnosis of PNH.
- Have active disease (≥1 sign or symptom of PNH or history of blood transfusion due to PNH within the last 3 months).
- Are new to treatment with a complement inhibitor or have not received complement inhibitor treatment of eculizumab in the last 3 months or ravulizumab in the last 6 months.
- NOTE: Additional study criteria apply.

## THANK YOU FOR CONSIDERING THE ACCESS-1 STUDY.

Clinical studies are research studies done to learn more about how the body responds to a certain treatment and whether that treatment works for a specific disease or medical condition.

You may or may not directly benefit from being in this study, but information learned may help others with PNH in the future.

Being in a clinical study is voluntary and you can stop participating at any time.

ACCESS-1 STUDY

REGN - ACCESS-1 Study - Trifold - 16-Aug-2022 - English (Master) - V2.0

PrintCode

REGENERON

## UNDERSTANDING THE

# ACCESS-1 STUDY



For adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are new to treatment* or have not received complement inhibitor treatment of eculizumab in the last 3 months or ravulizumab in the last 6 months.

*Treatment with a complement inhibitor.

## WHAT HAPPENS DURING THE STUDY?

If you agree to join the study, you will first have some tests and health checks to see if you are eligible (**Screening Period**). You will also be required to be up to date with certain vaccinations in order to lower your risk of infection.

If eligible, you will enter the **Treatment Period**, which lasts 26 weeks. During this period, you will have study visits to check on your health. Home healthcare or virtual visits may be available for certain visits.

## WHAT STUDY TREATMENT WILL I RECEIVE?

You will be randomly assigned to receive either the study drug combination (pozelimab + cemdisiran) or another treatment called ravulizumab.




## HOW ARE THE STUDY DRUGS GIVEN?

**Ravulizumab** is given as an infusion, which means slowly through a needle into a vein in the arm.

**Pozelimab + cemdisiran** are injected under the skin.*

*(The study staff may be able to train you or a caregiver on how to give your injections at home).*

You may also take **antibiotics** every day while receiving the study drug combination and for 1 year after your final dose to help lower the risk of infection (based on the advice of your doctor).

**The first dose of pozelimab is given as an infusion.*

## WHAT KIND OF TESTS AND HEALTH CHECKS WILL I HAVE?




*You will not have all of these tests at each visit. There may also be some additional tests. Talk to the study doctor for more information.*

More information about this study can be found in the full Informed Consent Form. Please ask your doctor if you have any questions.

To learn more about the ACCESS-1 Study, contact

_____

at _____